Senores Pharmaceuticals Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/xjmekxyi68km850bon4fi3ve.pdf

Key Takeaways


Regulated Markets: The Margin Engine

Swapnil Shah: "So far -- all your stated risks are correct. But so far, have we encountered any of those stated risks? The answer is no."

Emerging Markets: Waiting on the Turn

Swapnil Shah: "there are two issues that are driving, or maybe I would say not giving us, the kind of growth momentum that we need in the emerging market. One is the dollar appreciation across, right? So, people are kind of holding back and wanting their currency to stabilize."

Portfolio Build-Out: Launches, Facilities & Backward Integration

Swapnil Shah: "How large? It's difficult to state because in this emerging market, there are no IMS data or IQVIA data available where we could extrapolate and say we will gain 5%, 10% market share, and this will be the opportunity number for us."

Acquisitions & Turnarounds

Swapnil Shah: "So, revenue in three years has grown -- will grow about 3x. The registration that they had was about 48; we are at 394 today. So, the number of registrations has gone up by 6 times."

India Branded Generics: The Domestic Build


Margins & Cash Flow

Sanjay Majmudar: "I think a sustainable EBITDA of 28% to 30% is what we are looking at from next year onwards. And therefore, on a like-to-like basis, since we don't have too much of a debt burden, you can work out the PAT, but PAT as a percentage will improve by a couple of hundred BPS. That's what we are looking at."

Guidance & Commitments

CommitmentSpecificsTimeline
FY26 top-line growthAt least 50% growth over FY25FY26 full year
FY26 PAT growth100% growth over FY25FY26 full year
US facility capacity expansionThird line operational; fourth line by end FY26; total capacity ~200 cr unitsQ3 FY26 and end FY26
ANDA launches6-8 launches in H2 FY26; 8-10 in H1 FY27H2 FY26 and H1 FY27
India branded generics revenue~INR50 cr in FY26; ~INR100 cr next yearFY26 and FY27
PAN-India branded generics coverageAchieve full coverageEnd of FY26
API facility US FDA approvalFirst facility approval; second facility to manufacture key products post-approvalQ2 FY26-FY27
API facility revenueINR50-100 crores, largely from internal pipelineFY27
Emerging market EBITDA marginEarly double digits by end of this year; mid-teens over 2-3 yearsEnd FY26 and FY28-FY29
Sustainable EBITDA margin28-30%From FY27 onwards
Sustainable gross margin60-65%Ongoing
CDMO-CMO growth~30% CAGRNext 3-5 years
Ratnatris margin trajectoryLower teens this year, higher teens next yearFY26 and FY27
US sterile manufacturing facilityConstruction plannedQ2-Q3 FY27

Key Metrics

MetricQ2 FY26
Consolidated income₹162 cr, +61% YoY and +17% QoQ
EBITDA~₹50 cr, +113% YoY
EBITDA margin31%, +750 bps YoY and +580 bps QoQ
Profit after tax₹30 cr, +131% YoY
Regulated markets revenue₹107 cr, +87% YoY and +19% QoQ
Regulated markets EBITDA margin44%
Emerging markets revenue₹32 cr, +9% QoQ
Emerging markets EBITDA margin6.6%
Domestic branded generic revenue₹12 cr, >10x YoY
Operating cash flow (H1 FY26)~₹31 cr, >3x ₹9 cr in H1 FY25
Cash flow from operations to EBITDA (Q2)40%
Owned product portfolio81 products as of Q2 FY26
New products launched in Q28 products
Emerging markets registered products394 as of Sep 30, 2025, with 824 under registration
CDMO-CMO visible business for FY26$12 mn
Out-licensing income₹0.12 cr